Indication:  Suspected Heart Failure With abnormal ECG or Intermediate BNP (100-400) BNP:  Asymptomatic Murmur  Asymptomatic Cardiomegaly On CXR Direct.

Slides:



Advertisements
Similar presentations
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Advertisements

Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
BACK TO BASICS: PHARMACOLOGY CHAD C. CRIPE, MD Department of Anesthesiology & Critical Care Medicine Division of Cardiothoracic Anesthesiology The Children’s.
Heart Failure- II prognosis And Management
Heart Failure Management Focus on Primary Care Practice.
Modern Management of Heart Failure Dr Amanda Varnava Consultant Cardiologist Watford General Hospital & Imperial College Healthcare Trust.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Congestive Heart Failure Dr Ian Coombes Adopted from Duncan McRobbie Principal Clinical Pharmacist (with permission)
Congestive heart failure
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
Prepared by : Nehad J. Ahmed.  Heart failure, also known as congestive heart failure (CHF), means your heart can't pump enough blood to meet your body's.
Dorset Improving Diagnosis of Heart Failure Implementation of BNP Measuring in General Practice Ist Project Steering Group 13 th Sept 2011.
Dr. Jon Salisbury Visiting Physician Services A Member of VNA Health Group No Disclosures May 14, :40PM – 2:00PM ©AAHCM.
Management of Chronic Heart Failure SIGN 95
Pharmacological Treatment of Hypertension Update 2012.
Heart Failure and Qof Quiz Justin Walker October 2010.
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
HYPERTENSION NMP. How Common? 25% UK adults 25% UK adults > 50% adults over 60 > 50% adults over 60.
Modern Management of heart Failure Dr Amanda Varnava Consultant Cardiologist Watford & St Mary’s Hospitals.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie,
Dr Avinash Haridas Pillai
HEART FAILURE Prevalence increasing in our ageing population Incidence doubles with each decade between 40 and 80 At any age more common in men than women.
Heart Failure Hazel Phillips Cardiac Support Nurse Bedford Hospital NHS Trust.
Selection of Antihypertensive Drug. BP ClassificationSystolic BP, mm Hg Diastolic BP, mm Hg Normal
 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Patient case studies. JR is a 72 YO male with CHF, LVEF=32%. T2DM, HTN His meds include carvedilol 12.5mg q12hr, furosemide 40mg q day, and kcl 20meq.
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
Chronic Heart Failure Clinical case scenarios for primary care Educational Resource Implementing NICE guidance August 2010 NICE clinical guideline 108.
Cardiac Failure Richard Price Richard Price Consultant, Intensive Care, RAH. Consultant, Intensive Care, RAH.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Pharmacology of Heart failure
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
Drug List Accupril Quinapril – ACE Inhibitor – HTN & CHF.
CC-1 Integrated Summary of V-HeFT and A-HeFT Trials Milton Packer, MD University of Texas Southwestern Medical Center at Dallas.
Management of Heart Failure Overview Interactive exercise What colour are your sunglasses? Update on pathophysiology of HF Interactive case study Heart.
Congestive Heart Failure Arun Abbi M.D.. Outline 1. Classification and epidemiology 2. Pathophysiology 3. Diagnosis 4. Treatment 5. Conclusions.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.
ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS. benazepril (Lotensin), Captopril (Capoten), enalapril (Vasotec), enalaprilat (Vasotec(IV), fosinopril (Monopril),
CURRENT APPROACH TO THE TREATMENT OF CONGESTIVE HEART FAILURE.
Internal Medicine Workshop Series Laos September /October 2009
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
CHF Team Approach Peter Carson, MD Jacqueline Gannuscio, MSN, ACNP RN Washington DC.
Heart Failure: medication Types of Heart Failure Systolic (or squeezing) heart failure –Decreased pumping function of the heart, which results in fluid.
OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.
Interim Chair, Medicine Brigham and Women’s Hospital Boston, MA
HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.
Internal Medicine Workshop Series Laos September /October 2009.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
The African-American Heart Failure Trial (A-HeFT)
Ridha Chakeer MD PGY3. Objectives: Approximately 5.2 million Americans are affected  accounts for more than 3 million outpatient visits to primary care.
Guideline: Chronic Heart Failure
Windhi Dwijanarko RSU DADI KELUARGA, PURWOKERTO
Rapid access diagnostic pathway for suspected HF in primary care: The first 3 months... Dr Alan Japp Dr Sara Jenks Dr Clare McRae Dr Sebastian Peter.
Step Care Therapy for Hypertension in Diabetic Patients
Pharmacological Treatment of Hypertension Update 2012
Internal Medicine Workshop Series Laos September /October 2009
Presentation transcript:

Indication:  Suspected Heart Failure With abnormal ECG or Intermediate BNP ( ) BNP:  Asymptomatic Murmur  Asymptomatic Cardiomegaly On CXR Direct Access Echo RSCH

Footnote: Please do not use open access Echo but refer directly to consultant for: 1.Pts with symptoms and signs of CHF or very high BNP 2.Pts with symtomatic heart murmurs 3.Known heart failure with previous echo 4.Other cardiac problems Direct Access Echo RSCH

Drug therapy in CHF Diuretics ACE inhibitors B - blockers Spironolactone (Class III & IV patients) Angiotensin II receptor blockers (Alternative to ACE I) Hydralazine & ISDN (ACE I/ARB intolerance or in renal failure or in Afro- Carribeans as in the AHeFT trial) Digoxin if still symptomatic or in AF

Dose of ACE Inhibitors in CHF Enalapril2.5 mg od10-20 mg bd Lisinopril2.5 mg od20-40 mg od Perindopril2 mg od4 mg od Ramipril mg od10 mg od Initial Dose*Optimal Dose * If there are signs of dehydration, stop diuretics for 24 hrs before initial dose of ACE inhibitor

Summary of Drug Treatment of CHF CHF Confirmed ACE Inhibitors (or ARBs) Oedema Diuretics + Consider Spironolactone in Class III/IV pts No congestion Beta-blockers AF Digoxin + Warfarin Angina ISMN / Amlodipine

Conclusions BNP will help exclude heart failure ECG also useful in excluding CHF - can use this for triage Intermediate BNP levels can be found in CHF/IHD/ACS, treated CHF with non- cardiac cause of dyspnoea or non-CHF with non-cardiac cause of dyspnoea including PE and pneumonia Echocardiography for definitive diagnosis BNP and open access echocardiography now available for primary care in Guildford